<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34830872</PMID><DateRevised><Year>2024</Year><Month>04</Month><Day>04</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2072-6694</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>22</Issue><PubDate><Year>2021</Year><Month>Nov</Month><Day>15</Day></PubDate></JournalIssue><Title>Cancers</Title><ISOAbbreviation>Cancers (Basel)</ISOAbbreviation></Journal><ArticleTitle>Blood Cytokine Analysis Suggests That SARS-CoV-2 Infection Results in a Sustained Tumour Promoting Environment in Cancer Patients.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">5718</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/cancers13225718</ELocationID><Abstract><AbstractText>Cytokines, chemokines, and (angiogenic) growth factors (CCGs) have been shown to play an intricate role in the progression of both solid and haematological malignancies. Recent studies have shown that SARS-CoV-2 infection leads to a worse outcome in cancer patients, especially in haematological malignancy patients. Here, we investigated how SARS-CoV-2 infection impacts the already altered CCG levels in solid or haematological malignancies, specifically, whether there is a protective effect or rather a potentially higher risk for major COVID-19 complications in cancer patients due to elevated CCGs linked to cancer progression. Serially analysing immune responses with 55 CCGs in cancer patients under active treatment with or without SARS-CoV-2 infection, we first showed that cancer patients without SARS-CoV-2 infection (<i>n</i> = 54) demonstrate elevated levels of 35 CCGs compared to the non-cancer, non-infected control group of health care workers (<i>n</i> = 42). Of the 35 CCGs, 19 were common to both the solid and haematological malignancy groups and comprised previously described cytokines such as IL-6, TNF-&#x3b1;, IL-1Ra, IL-17A, and VEGF, but also several less well described cytokines/chemokines such as Fractalkine, Tie-2, and T cell chemokine CTACK. Importantly, we show here that 7 CCGs are significantly altered in SARS-CoV-2 exposed cancer patients (<i>n</i> = 52). Of these, TNF-&#x3b1;, IFN-&#x3b2;, TSLP, and sVCAM-1, identified to be elevated in haematological cancers, are also known tumour-promoting factors. Longitudinal analysis conducted over 3 months showed persistence of several tumour-promoting CCGs in SARS-CoV-2 exposed cancer patients. These data demonstrate a need for increased vigilance for haematological malignancy patients as a part of long COVID follow-up.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>De Winter</LastName><ForeName>Fien H R</ForeName><Initials>FHR</Initials><Identifier Source="ORCID">0000-0003-3803-7813</Identifier><AffiliationInfo><Affiliation>Molecular Pathology Group, Laboratory of Cell Biology &amp; Histology, Faculty of Medicine and Health Sciences, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hotterbeekx</LastName><ForeName>An</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-3356-4032</Identifier><AffiliationInfo><Affiliation>Molecular Pathology Group, Laboratory of Cell Biology &amp; Histology, Faculty of Medicine and Health Sciences, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huizing</LastName><ForeName>Manon T</ForeName><Initials>MT</Initials><Identifier Source="ORCID">0000-0001-5331-9486</Identifier><AffiliationInfo><Affiliation>Multidisciplinary Oncologic Centre Antwerp (MOCA), Antwerp University Hospital, Drie Eikenstraat 655, 2650 Edegem, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biobank Antwerp, Antwerp University Hospital, Drie Eikenstraat 655, 2650 Edegem, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Konnova</LastName><ForeName>Angelina</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-9353-8026</Identifier><AffiliationInfo><Affiliation>Molecular Pathology Group, Laboratory of Cell Biology &amp; Histology, Faculty of Medicine and Health Sciences, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fransen</LastName><ForeName>Erik</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>StatUa, Center for Statistics, University of Antwerp, 2000 Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jongers</LastName><ForeName>Bart's</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Molecular Pathology Group, Laboratory of Cell Biology &amp; Histology, Faculty of Medicine and Health Sciences, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jairam</LastName><ForeName>Ravi Kumar</ForeName><Initials>RK</Initials><AffiliationInfo><Affiliation>Molecular Pathology Group, Laboratory of Cell Biology &amp; Histology, Faculty of Medicine and Health Sciences, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Averbeke</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Molecular Pathology Group, Laboratory of Cell Biology &amp; Histology, Faculty of Medicine and Health Sciences, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moons</LastName><ForeName>Pieter</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-9830-0444</Identifier><AffiliationInfo><Affiliation>Biobank Antwerp, Antwerp University Hospital, Drie Eikenstraat 655, 2650 Edegem, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roelant</LastName><ForeName>Ella</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>StatUa, Center for Statistics, University of Antwerp, 2000 Antwerp, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Trial Center (CTC), CRC Antwerp, Antwerp University Hospital, University of Antwerp, Drie Eikenstraat 655, 2650 Edegem, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le Blon</LastName><ForeName>Debbie</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vanden Berghe</LastName><ForeName>Wim</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0003-0161-7355</Identifier><AffiliationInfo><Affiliation>PPES Lab Protein Chemistry, Proteomics &amp; Epigenetic Signaling, IPPON, Department Biomedical Sciences, University Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Janssens</LastName><ForeName>Annelies</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Multidisciplinary Oncologic Centre Antwerp (MOCA), Antwerp University Hospital, Drie Eikenstraat 655, 2650 Edegem, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lybaert</LastName><ForeName>Willem</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, AZ Nikolaas, Moerlandstraat 1, 9100 Sint-Niklaas, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Croes</LastName><ForeName>Lieselot</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Integrated Cancer Center Ghent, Department of Medical Oncology, AZ Maria Middelares, Buitenring Sint-Denijs 30, 9000 Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vulsteke</LastName><ForeName>Christof</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Clinical Trial Center (CTC), CRC Antwerp, Antwerp University Hospital, University of Antwerp, Drie Eikenstraat 655, 2650 Edegem, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Integrated Cancer Center Ghent, Department of Medical Oncology, AZ Maria Middelares, Buitenring Sint-Denijs 30, 9000 Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malhotra-Kumar</LastName><ForeName>Surbhi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goossens</LastName><ForeName>Herman</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berneman</LastName><ForeName>Zwi</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Multidisciplinary Oncologic Centre Antwerp (MOCA), Antwerp University Hospital, Drie Eikenstraat 655, 2650 Edegem, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peeters</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Multidisciplinary Oncologic Centre Antwerp (MOCA), Antwerp University Hospital, Drie Eikenstraat 655, 2650 Edegem, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Dam</LastName><ForeName>Peter A</ForeName><Initials>PA</Initials><Identifier Source="ORCID">0000-0002-9184-7703</Identifier><AffiliationInfo><Affiliation>Multidisciplinary Oncologic Centre Antwerp (MOCA), Antwerp University Hospital, Drie Eikenstraat 655, 2650 Edegem, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar-Singh</LastName><ForeName>Samir</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-9466-6732</Identifier><AffiliationInfo><Affiliation>Molecular Pathology Group, Laboratory of Cell Biology &amp; Histology, Faculty of Medicine and Health Sciences, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>000100470</GrantID><Agency>Kom Op Tegen Kanker</Agency><Country/></Grant><Grant><GrantID>2020</GrantID><Agency>UZA Foundation grant</Agency><Country/></Grant><Grant><GrantID>42839</GrantID><Agency>University of Antwerp</Agency><Country/></Grant><Grant><GrantID>s30729</GrantID><Agency>University of Antwerp</Agency><Country/></Grant><Grant><GrantID>115523 and 115737</GrantID><Agency>Innovative Medicines Initiative</Agency><Country/></Grant><Grant><GrantID>Orchestra</GrantID><Agency>Horizon 2020</Agency><Country/></Grant><Grant><GrantID>FWO-SB151525 and FWO-1S93418N</GrantID><Agency>Research Foundation - Flanders</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Cancers (Basel)</MedlineTA><NlmUniqueID>101526829</NlmUniqueID><ISSNLinking>2072-6694</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Th1</Keyword><Keyword MajorTopicYN="N">Th17</Keyword><Keyword MajorTopicYN="N">Th2</Keyword><Keyword MajorTopicYN="N">anti-inflammatory</Keyword><Keyword MajorTopicYN="N">haematological cancers</Keyword><Keyword MajorTopicYN="N">immune response</Keyword><Keyword MajorTopicYN="N">pro-inflammatory</Keyword><Keyword MajorTopicYN="N">solid cancers</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>10</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>11</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>11</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>27</Day><Hour>1</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>28</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>11</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34830872</ArticleId><ArticleId IdType="pmc">PMC8616215</ArticleId><ArticleId IdType="doi">10.3390/cancers13225718</ArticleId><ArticleId IdType="pii">cancers13225718</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature. 2008;454:436&#x2013;444. doi: 10.1038/nature07205.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature07205</ArticleId><ArticleId IdType="pubmed">18650914</ArticleId></ArticleIdList></Reference><Reference><Citation>Grivennikov S.I., Greten F.R., Karin M. Immunity, Inflammation, and Cancer. Cell. 2010;140:883&#x2013;899. doi: 10.1016/j.cell.2010.01.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2010.01.025</ArticleId><ArticleId IdType="pmc">PMC2866629</ArticleId><ArticleId IdType="pubmed">20303878</ArticleId></ArticleIdList></Reference><Reference><Citation>Lan T., Chen L., Wei X. Inflammatory Cytokines in Cancer: Comprehensive Understanding and Clinical Progress in Gene Therapy. Cells. 2021;10:100. doi: 10.3390/cells10010100.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10010100</ArticleId><ArticleId IdType="pmc">PMC7827947</ArticleId><ArticleId IdType="pubmed">33429846</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson D.E., O&#x2019;Keefe R.A., Grandis J.R. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat. Rev. Clin. Oncol. 2018;15:234&#x2013;248. doi: 10.1038/nrclinonc.2018.8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrclinonc.2018.8</ArticleId><ArticleId IdType="pmc">PMC5858971</ArticleId><ArticleId IdType="pubmed">29405201</ArticleId></ArticleIdList></Reference><Reference><Citation>Balkwill F. TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev. 2006;25:409&#x2013;416. doi: 10.1007/s10555-006-9005-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10555-006-9005-3</ArticleId><ArticleId IdType="pubmed">16951987</ArticleId></ArticleIdList></Reference><Reference><Citation>Do H.T.T., Lee C.H., Cho J. Chemokines and their Receptors: Multifaceted Roles in Cancer Progression and Potential Value as Cancer Prognostic Markers. Cancers. 2020;12:287. doi: 10.3390/cancers12020287.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers12020287</ArticleId><ArticleId IdType="pmc">PMC7072521</ArticleId><ArticleId IdType="pubmed">31991604</ArticleId></ArticleIdList></Reference><Reference><Citation>Tokunaga R., Nakagawa S., Sakamoto Y., Nakamura K., Naseem M., Izumi D., Kosumi K., Taki K., Higashi T., Miyata T., et al. 12-Chemokine signature, a predictor of tumor recurrence in colorectal cancer. Int. J. Cancer. 2020;147:532&#x2013;541. doi: 10.1002/ijc.32982.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.32982</ArticleId><ArticleId IdType="pmc">PMC9371443</ArticleId><ArticleId IdType="pubmed">32191346</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z.Y., He W.Z., Peng L.X., Jia W.H., Guo R.P., Xia L.P., Qian C.N. A prognostic classifier consisting of 17 circulating cytokines is a novel predictor of overall survival for metastatic colorectal cancer patients. Int. J. Cancer. J. Int. Cancer. 2015;136:584&#x2013;592. doi: 10.1002/ijc.29017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.29017</ArticleId><ArticleId IdType="pubmed">24916890</ArticleId></ArticleIdList></Reference><Reference><Citation>Capone F., Guerriero E., Sorice A., Colonna G., Ciliberto G., Costantini S. Serum Cytokinome Profile Evaluation: A Tool to Define New Diagnostic and Prognostic Markers of Cancer Using Multiplexed Bead-Based Immunoassays. Mediat. Inflamm. 2016;2016:3064643. doi: 10.1155/2016/3064643.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2016/3064643</ArticleId><ArticleId IdType="pmc">PMC5168457</ArticleId><ArticleId IdType="pubmed">28050120</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiels M.S., Pfeiffer R.M., Hildesheim A., Engels E.A., Kemp T.J., Park J.-H., Katki H.A., Koshiol J., Shelton G., Caporaso N.E., et al. Circulating Inflammation Markers and Prospective Risk for Lung Cancer. JNCI J. Natl. Cancer Inst. 2013;105:1871&#x2013;1880. doi: 10.1093/jnci/djt309.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnci/djt309</ArticleId><ArticleId IdType="pmc">PMC3888091</ArticleId><ArticleId IdType="pubmed">24249745</ArticleId></ArticleIdList></Reference><Reference><Citation>Arfsten H., Cho A., Freitag C., Raderer M., Goliasch G., Bartko P.E., Wurm R., Strunk G., Gisslinger H., Marosi C., et al. GDF-15 in solid vs non-solid treatment-na&#xef;ve malignancies. Eur. J. Clin. Investig. 2019;49:e13168. doi: 10.1111/eci.13168.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/eci.13168</ArticleId><ArticleId IdType="pmc">PMC6899906</ArticleId><ArticleId IdType="pubmed">31463975</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinstein P.S., Skinner M., Sipe J.D., Lokich J.J., Zamcheck N., Cohen A.S. Acute-phase proteins or tumour markers: The role of SAA, SAP, CRP and CEA as indicators of metastasis in a broad spectrum of neoplastic diseases. Scand. J. Immunol. 1984;19:193&#x2013;198. doi: 10.1111/j.1365-3083.1984.tb00919.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-3083.1984.tb00919.x</ArticleId><ArticleId IdType="pubmed">6200925</ArticleId></ArticleIdList></Reference><Reference><Citation>Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology. 2005;69((Suppl. 3)):4&#x2013;10. doi: 10.1159/000088478.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000088478</ArticleId><ArticleId IdType="pubmed">16301830</ArticleId></ArticleIdList></Reference><Reference><Citation>Medinger M., Passweg J. Role of tumour angiogenesis in haematological malignancies. Swiss Med. Wkly. 2014;144:w14050. doi: 10.4414/smw.2014.14050.</Citation><ArticleIdList><ArticleId IdType="doi">10.4414/smw.2014.14050</ArticleId><ArticleId IdType="pubmed">25375891</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdul-Jawad S., Ba&#xf9; L., Alaguthurai T., Del Molino Del Barrio I., Laing A.G., Hayday T.S., Monin L., Mu&#xf1;oz-Ruiz M., McDonald L., Francos Quijorna I., et al. Acute Immune Signatures and Their Legacies in Severe Acute Respiratory Syndrome Coronavirus-2 Infected Cancer Patients. Cancer Cell. 2021;39:257&#x2013;275.e256. doi: 10.1016/j.ccell.2021.01.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccell.2021.01.001</ArticleId><ArticleId IdType="pmc">PMC7833668</ArticleId><ArticleId IdType="pubmed">33476581</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang W., Guan W., Chen R., Wang W., Li J., Xu K., Li C., Ai Q., Lu W., Liang H., et al. Cancer patients in SARS-CoV-2 infection: A nationwide analysis in China. Lancet Oncol. 2020;21:335&#x2013;337. doi: 10.1016/S1470-2045(20)30096-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(20)30096-6</ArticleId><ArticleId IdType="pmc">PMC7159000</ArticleId><ArticleId IdType="pubmed">32066541</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai M., Liu D., Liu M., Zhou F., Li G., Chen Z., Zhang Z., You H., Wu M., Zheng Q., et al. Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak. Cancer Discov. 2020;10:783&#x2013;791. doi: 10.1158/2159-8290.Cd-20-0422.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2159-8290.Cd-20-0422</ArticleId><ArticleId IdType="pmc">PMC7309152</ArticleId><ArticleId IdType="pubmed">32345594</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Y., Qiu X., Wang C., Zhao J., Jiang X., Niu W., Huang J., Zhang F. Cancer associates with risk and severe events of COVID-19: A systematic review and meta-analysis. Int. J. Cancer. 2021;148:363&#x2013;374. doi: 10.1002/ijc.33213.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.33213</ArticleId><ArticleId IdType="pmc">PMC7404763</ArticleId><ArticleId IdType="pubmed">32683687</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee L.Y., Cazier J.B., Angelis V., Arnold R., Bisht V., Campton N.A., Chackathayil J., Cheng V.W., Curley H.M., Fittall M.W., et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: A prospective cohort study. Lancet. 2020;395:1919&#x2013;1926. doi: 10.1016/S0140-6736(20)31173-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31173-9</ArticleId><ArticleId IdType="pmc">PMC7255715</ArticleId><ArticleId IdType="pubmed">32473682</ArticleId></ArticleIdList></Reference><Reference><Citation>van Dam P.A., Huizing M., Mestach G., Dierckxsens S., Tjalma W., Trinh X.B., Papadimitriou K., Altintas S., Vermorken J., Vulsteke C., et al. SARS-CoV-2 and cancer: Are they really partners in crime? Cancer Treat. Rev. 2020;89:102068. doi: 10.1016/j.ctrv.2020.102068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ctrv.2020.102068</ArticleId><ArticleId IdType="pmc">PMC7351667</ArticleId><ArticleId IdType="pubmed">32731090</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucas C., Wong P., Klein J., Castro T.B.R., Silva J., Sundaram M., Ellingson M.K., Mao T., Oh J.E., Israelow B., et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature. 2020;584:463&#x2013;469. doi: 10.1038/s41586-020-2588-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2588-y</ArticleId><ArticleId IdType="pmc">PMC7477538</ArticleId><ArticleId IdType="pubmed">32717743</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497&#x2013;506. doi: 10.1016/S0140-6736(20)30183-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30183-5</ArticleId><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Valle D.M., Kim-Schulze S., Huang H.H., Beckmann N.D., Nirenberg S., Wang B., Lavin Y., Swartz T.H., Madduri D., Stock A., et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat. Med. 2020;26:1636&#x2013;1643. doi: 10.1038/s41591-020-1051-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-1051-9</ArticleId><ArticleId IdType="pmc">PMC7869028</ArticleId><ArticleId IdType="pubmed">32839624</ArticleId></ArticleIdList></Reference><Reference><Citation>Abers M.S., Delmonte O.M., Ricotta E.E., Fintzi J., Fink D.L., de Jesus A.A.A., Zarember K.A., Alehashemi S., Oikonomou V., Desai J.V., et al. An immune-based biomarker signature is associated with mortality in COVID-19 patients. JCI Insight. 2021;6:e144455. doi: 10.1172/jci.insight.144455.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.144455</ArticleId><ArticleId IdType="pmc">PMC7821609</ArticleId><ArticleId IdType="pubmed">33232303</ArticleId></ArticleIdList></Reference><Reference><Citation>Young B.E., Ong S.W.X., Ng L.F.P., Anderson D.E., Chia W.N., Chia P.Y., Ang L.W., Mak T.M., Kalimuddin S., Chai L.Y.A., et al. Viral dynamics and immune correlates of COVID-19 disease severity. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2020;73:e2932&#x2013;e2942. doi: 10.1093/cid/ciaa1280.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1280</ArticleId><ArticleId IdType="pmc">PMC7499509</ArticleId><ArticleId IdType="pubmed">32856707</ArticleId></ArticleIdList></Reference><Reference><Citation>van Dam P., Huizing M., Roelant E., Hotterbeekx A., De Winter F.H.R., Kumar-Singh S., Moons P., Amajoud Z., Vulsteke C., Croes L., et al. Immunoglobin G/total antibody testing for SARS-CoV-2: A prospective cohort study of ambulatory patients and health care workers in two Belgian oncology units comparing three commercial tests. Eur. J. Cancer. 2021;148:328&#x2013;339. doi: 10.1016/j.ejca.2021.02.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejca.2021.02.024</ArticleId><ArticleId IdType="pmc">PMC7914028</ArticleId><ArticleId IdType="pubmed">33773276</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Working Group on the Clinical Characterisation and Management of COVID-19 Infection A minimal common outcome measure set for COVID-19 clinical research. Lancet. Infect. Dis. 2020;20:e192&#x2013;e197. doi: 10.1016/S1473-3099(20)30483-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30483-7</ArticleId><ArticleId IdType="pmc">PMC7292605</ArticleId><ArticleId IdType="pubmed">32539990</ArticleId></ArticleIdList></Reference><Reference><Citation>DeNardo D.G., Barreto J.B., Andreu P., Vasquez L., Tawfik D., Kolhatkar N., Coussens L.M. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell. 2009;16:91&#x2013;102. doi: 10.1016/j.ccr.2009.06.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccr.2009.06.018</ArticleId><ArticleId IdType="pmc">PMC2778576</ArticleId><ArticleId IdType="pubmed">19647220</ArticleId></ArticleIdList></Reference><Reference><Citation>Kermani P., Hempstead B. Brain-derived neurotrophic factor: A newly described mediator of angiogenesis. Trends Cardiovasc. Med. 2007;17:140&#x2013;143. doi: 10.1016/j.tcm.2007.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tcm.2007.03.002</ArticleId><ArticleId IdType="pmc">PMC2268985</ArticleId><ArticleId IdType="pubmed">17482097</ArticleId></ArticleIdList></Reference><Reference><Citation>Thwaites R.S., Sanchez Sevilla Uruchurtu A., Siggins M.K., Liew F., Russell C.D., Moore S.C., Fairfield C., Carter E., Abrams S., Short C.E., et al. Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19. Sci. Immunol. 2021;6:eabg9873. doi: 10.1126/sciimmunol.abg9873.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abg9873</ArticleId><ArticleId IdType="pmc">PMC8128298</ArticleId><ArticleId IdType="pubmed">33692097</ArticleId></ArticleIdList></Reference><Reference><Citation>Burke H., Freeman A., Cellura D.C., Stuart B.L., Brendish N.J., Poole S., Borca F., Phan H.T.T., Sheard N., Williams S., et al. Inflammatory phenotyping predicts clinical outcome in COVID-19. Respir. Res. 2020;21:245. doi: 10.1186/s12931-020-01511-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12931-020-01511-z</ArticleId><ArticleId IdType="pmc">PMC7506817</ArticleId><ArticleId IdType="pubmed">32962703</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y., Shen C., Li J., Yuan J., Wei J., Huang F., Wang F., Li G., Li Y., Xing L., et al. Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19. J. Allergy Clin. Immunol. 2020;146:119&#x2013;127.e114. doi: 10.1016/j.jaci.2020.04.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2020.04.027</ArticleId><ArticleId IdType="pmc">PMC7189843</ArticleId><ArticleId IdType="pubmed">32360286</ArticleId></ArticleIdList></Reference><Reference><Citation>Ackermann M., Verleden S.E., Kuehnel M., Haverich A., Welte T., Laenger F., Vanstapel A., Werlein C., Stark H., Tzankov A., et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N. Engl. J. Med. 2020;383:120&#x2013;128. doi: 10.1056/NEJMoa2015432.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2015432</ArticleId><ArticleId IdType="pmc">PMC7412750</ArticleId><ArticleId IdType="pubmed">32437596</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitajima D., Kasamatsu A., Nakashima D., Miyamoto I., Kimura Y., Saito T., Suzuki T., Endo-Sakamoto Y., Shiiba M., Tanzawa H., et al. Tie2 Regulates Tumor Metastasis of Oral Squamous Cell Carcinomas. J. Cancer. 2016;7:600&#x2013;607. doi: 10.7150/jca.13820.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/jca.13820</ArticleId><ArticleId IdType="pmc">PMC4820737</ArticleId><ArticleId IdType="pubmed">27053959</ArticleId></ArticleIdList></Reference><Reference><Citation>Craver B.M., El Alaoui K., Scherber R.M., Fleischman A.G. The Critical Role of Inflammation in the Pathogenesis and Progression of Myeloid Malignancies. Cancers. 2018;10:104. doi: 10.3390/cancers10040104.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers10040104</ArticleId><ArticleId IdType="pmc">PMC5923359</ArticleId><ArticleId IdType="pubmed">29614027</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervantes-Villagrana R.D., Albores-Garcia D., Cervantes-Villagrana A.R., Garcia-Acevez S.J. Tumor-induced neurogenesis and immune evasion as targets of innovative anti-cancer therapies. Signal Transduct. Target. Ther. 2020;5:99. doi: 10.1038/s41392-020-0205-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-020-0205-z</ArticleId><ArticleId IdType="pmc">PMC7303203</ArticleId><ArticleId IdType="pubmed">32555170</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen M., Wu Y., Jia W., Yin M., Hu Z., Wang R., Li W., Wang G. The predictive value of serum amyloid A and C-reactive protein levels for the severity of coronavirus disease 2019. Am. J. Transl. Res. 2020;12:4569&#x2013;4575.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7476119</ArticleId><ArticleId IdType="pubmed">32913530</ArticleId></ArticleIdList></Reference><Reference><Citation>Sack G.H., Jr. Serum amyloid A&#x2013;A review. Mol. Med. 2018;24:46. doi: 10.1186/s10020-018-0047-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s10020-018-0047-0</ArticleId><ArticleId IdType="pmc">PMC6117975</ArticleId><ArticleId IdType="pubmed">30165816</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbas A.K. The Surprising Story of IL-2: From Experimental Models to Clinical Application. Am. J. Pathol. 2020;190:1776&#x2013;1781. doi: 10.1016/j.ajpath.2020.05.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2020.05.007</ArticleId><ArticleId IdType="pubmed">32828360</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu J.Y., Li G.C., Wang W.M., Zhu J.G., Li Y.F., Zhou G.H., Sun Q.B. Transfection of colorectal cancer cells with chemokine MCP-3 (monocyte chemotactic protein-3) gene retards tumor growth and inhibits tumor metastasis. World J. Gastroenterol. 2002;8:1067&#x2013;1072. doi: 10.3748/wjg.v8.i6.1067.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v8.i6.1067</ArticleId><ArticleId IdType="pmc">PMC4656382</ArticleId><ArticleId IdType="pubmed">12439927</ArticleId></ArticleIdList></Reference><Reference><Citation>Okada M., Saio M., Kito Y., Ohe N., Yano H., Yoshimura S., Iwama T., Takami T. Tumor-associated macrophage/microglia infiltration in human gliomas is correlated with MCP-3, but not MCP-1. Int. J. Oncol. 2009;34:1621&#x2013;1627. doi: 10.3892/ijo_00000292.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ijo_00000292</ArticleId><ArticleId IdType="pubmed">19424580</ArticleId></ArticleIdList></Reference><Reference><Citation>Corrales L., McWhirter S.M., Dubensky T.W., Jr., Gajewski T.F. The host STING pathway at the interface of cancer and immunity. J. Clin. Investig. 2016;126:2404&#x2013;2411. doi: 10.1172/JCI86892.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI86892</ArticleId><ArticleId IdType="pmc">PMC4922692</ArticleId><ArticleId IdType="pubmed">27367184</ArticleId></ArticleIdList></Reference><Reference><Citation>Snell L.M., McGaha T.L., Brooks D.G. Type I Interferon in Chronic Virus Infection and Cancer. Trends Immunol. 2017;38:542&#x2013;557. doi: 10.1016/j.it.2017.05.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2017.05.005</ArticleId><ArticleId IdType="pmc">PMC8059441</ArticleId><ArticleId IdType="pubmed">28579323</ArticleId></ArticleIdList></Reference><Reference><Citation>Corren J., Ziegler S.F. TSLP: From allergy to cancer. Nat. Immunol. 2019;20:1603&#x2013;1609. doi: 10.1038/s41590-019-0524-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-019-0524-9</ArticleId><ArticleId IdType="pubmed">31745338</ArticleId></ArticleIdList></Reference><Reference><Citation>Tokunaga R., Zhang W., Naseem M., Puccini A., Berger M.D., Soni S., McSkane M., Baba H., Lenz H.J. CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation&#x2013;A target for novel cancer therapy. Cancer Treat. Rev. 2018;63:40&#x2013;47. doi: 10.1016/j.ctrv.2017.11.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ctrv.2017.11.007</ArticleId><ArticleId IdType="pmc">PMC5801162</ArticleId><ArticleId IdType="pubmed">29207310</ArticleId></ArticleIdList></Reference><Reference><Citation>Niyongere S., Lucas N., Zhou J.M., Sansil S., Pomicter A.D., Balasis M.E., Robinson J., Kroeger J., Zhang Q., Zhao Y.L., et al. Heterogeneous expression of cytokines accounts for clinical diversity and refines prognostication in CMML. Leukemia. 2019;33:205&#x2013;216. doi: 10.1038/s41375-018-0203-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41375-018-0203-0</ArticleId><ArticleId IdType="pmc">PMC7787307</ArticleId><ArticleId IdType="pubmed">30026572</ArticleId></ArticleIdList></Reference><Reference><Citation>Garner H., de Visser K.E. Immune crosstalk in cancer progression and metastatic spread: A complex conversation. Nat. Rev. Immunol. 2020;20:483&#x2013;497. doi: 10.1038/s41577-019-0271-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-019-0271-z</ArticleId><ArticleId IdType="pubmed">32024984</ArticleId></ArticleIdList></Reference><Reference><Citation>Saini G., Aneja R. Cancer as a prospective sequela of long COVID-19. BioEssays News Rev. Mol. Cell. Dev. Biol. 2021;43:e2000331. doi: 10.1002/bies.202000331.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bies.202000331</ArticleId><ArticleId IdType="pmc">PMC8206711</ArticleId><ArticleId IdType="pubmed">33914346</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G., Fan Y., Lai Y., Han T., Li Z., Zhou P., Pan P., Wang W., Hu D., Liu X., et al. Coronavirus infections and immune responses. J. Med. Virol. 2020;92:424&#x2013;432. doi: 10.1002/jmv.25685.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25685</ArticleId><ArticleId IdType="pmc">PMC7166547</ArticleId><ArticleId IdType="pubmed">31981224</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook H., Raza S., Nowell J., Young M., Edison P. Long covid&#x2014;mechanisms, risk factors, and management. BMJ. 2021;374:n1648. doi: 10.1136/bmj.n1648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1648</ArticleId><ArticleId IdType="pubmed">34312178</ArticleId></ArticleIdList></Reference><Reference><Citation>Herzog S., De Bie J., Abrams S., Wouters I., Ekinci E., Patteet L., Coppens A., De Spiegeleer S., Beutels P., Van Damme P., et al. Seroprevalence of IgG antibodies against SARS coronavirus 2 in Belgium&#x2013;A serial prospective cross-sectional nationwide study of residual samples. medRxiv. 2021 doi: 10.1101/2020.06.08.20125179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.06.08.20125179</ArticleId><ArticleId IdType="pmc">PMC8895468</ArticleId><ArticleId IdType="pubmed">35241216</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>